Maggie Leong is a postdoctoral researcher working on peptide therapeutics development for the treatment of rare neurological diseases including Huntington’s Disease (HD), Spinocerebellar ataxias (SCAs), and Amyotrophic Lateral Sclerosis (ALS). She began her research journey on peptide biologics for pathogenic RNA targeting in 2018, when she started her PhD study. In 2023, her PhD supervisor Professor Edwin Chan and her co-founded a start-up biotechnology company named Rare Power with our vision to develop first-in-class innovative therapeutics for rare diseases. Some of our pipelines are currently undergoing the preclinical testing stages. In this workshop, she hopes to equip herself with the latest knowledge and methodologies for analysing and optimising dosing regimens to achieve favourable pharmacokinetics and pharmacodynamics profiles for treatments.